Baxter Ventures Leads $4.9M Series B Round for Gliknik
October 9, 2012
Gliknik, a biopharmaceuticals company developing therapies for cancer and immune/inflammatory disorders, has secured $4.9 million in Series B financing led by Baxter Ventures. LifeTech Development Partners and a number of other previous backers also participated. Gliknick has now collected $14.3 million in total venture funding.